Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.rmed.2021.106355 http://scihub22266oqcxt.onion/10.1016/j.rmed.2021.106355 33721697!7935673!33721697     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Respir+Med 2021 ; 180 (ä): 106355 Nephropedia Template TP {{tp|p=33721697|t=2021. SARS-CoV-2 vaccines: A critical perspective through efficacy data and barriers to herd immunity |pdf=|usr=}}{{33721697}} gab.com Text SARS-CoV-2 vaccines: A critical perspective through efficacy data and barriers to herd immunity JO: Respir Med http://www.kidney.de/pget.php?&tw=1&pmid=33721697 #FOAvip Non-pharmacological interventions and tracing-testing strategy proved insufficient to reduce SARS-CoV-2 spreading worldwide. Several vaccines with different mechanisms of action are currently under development. This review describes the potential target antigens evaluated for SARS-CoV-2 vaccine in the context of both conventional and next-generation platforms. We reported experimental data from phase-3 trials with a focus on different definitions of efficacy as well as factors affecting real-life effectiveness of SARS-CoV-2 vaccination, including logistical issues associated to vaccine availability, delivery, and immunization strategies. On this background, new variants of SARS-CoV-2 are discussed. We also provided a critical view on vaccination in special populations at higher risk of infection or severe disease as elderly people, pregnant women and immunocompromised patients. A final paragraph addresses safety on the light of the unprecedented reduction of length of the vaccine development process and faster authorization. Twit Text FOAVip SARS-CoV-2 vaccines: A critical perspective through efficacy data and barriers to herd immunity ????Respir Med http://www.kidney.de/pget.php?&tw=1&pmid=33721697 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33721697 #FOAvip English Wikipedia <ref>{{Cite pmid|33721697}}</ref> SARS-CoV-2 vaccines: A critical perspective through efficacy data and barriers to herd immunity #MMPMID33721697 Blasi F; Gramegna A; Sotgiu G; Saderi L; Voza A; Aliberti S; Amati F Respir Med 2021[Apr]; 180 (ä): 106355 PMID33721697show ga Non-pharmacological interventions and tracing-testing strategy proved insufficient to reduce SARS-CoV-2 spreading worldwide. Several vaccines with different mechanisms of action are currently under development. This review describes the potential target antigens evaluated for SARS-CoV-2 vaccine in the context of both conventional and next-generation platforms. We reported experimental data from phase-3 trials with a focus on different definitions of efficacy as well as factors affecting real-life effectiveness of SARS-CoV-2 vaccination, including logistical issues associated to vaccine availability, delivery, and immunization strategies. On this background, new variants of SARS-CoV-2 are discussed. We also provided a critical view on vaccination in special populations at higher risk of infection or severe disease as elderly people, pregnant women and immunocompromised patients. A final paragraph addresses safety on the light of the unprecedented reduction of length of the vaccine development process and faster authorization. |*Immunity, Herd[MESH] |COVID-19 Vaccines/*pharmacology[MESH] |COVID-19/epidemiology/immunology/*prevention & control[MESH] |Humans[MESH] |Pandemics[MESH] |SARS-CoV-2/*immunology[MESH]SARS-CoV-2 vaccines: A critical perspective through efficacy data and (epmc).pdf DeepDyve Pubget Overpricing